Universal, off‑the‑shelf CAR‑T cell therapies using gene‑edited donor T cells are beginning to overcome key barriers of cost, delay and access in cell‑based cancer treatment.
Valueinvestor on Freepik
One of the most dramatic improvements in cancer therapy over the past several years has been the adoption of cell-based therapies. Many of these involve CAR T therapies—treatments in which immune system cells are modified to attack cancer cells. To date, the great majority of these therapies have used the patient’s own immune cells: the cells are extracted, modified, expanded and then reinfused.
The good news is that some of these therapies have had remarkable results. Nonetheless, there are significant barriers to their widespread adoption. These include variability in patients’ cells, the time required for…